Market Exclusive

ABAXIS, INC. (NASDAQ:ABAX) Files An 8-K Results of Operations and Financial Condition

ABAXIS, INC. (NASDAQ:ABAX) Files An 8-K Results of Operations and Financial Condition

Item 2.02


Results of Operations and Financial Condition.

The information in this Item 2.02, including the exhibit attached
hereto, is being furnished and shall not be deemed filed for the
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended or the Exchange Act, or otherwise subject to the
liabilities of that Section. The information in this Item 2.02
shall not be deemed incorporated by reference into any filing
under the Securities Act of 1933, as amended, or the Exchange Act
regardless of any general incorporation language in such filing.

On January 10, 2017, Abaxis, Inc. announced its preliminary
financial results for the three months ended December 31, 2016
and certain other preliminary financial information. A copy of
Abaxis press release announcing these preliminary financial
results and certain other preliminary financial information is
attached hereto as Exhibit 99.1 and is incorporated by reference
herein.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits.

The following exhibit is furnished with this report on Form 8-K:

Exhibit No.

Description

99.1

Press release dated January 10, 2017

About ABAXIS, INC. (NASDAQ:ABAX)
Abaxis, Inc. is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The Company markets and sells its products around the world through independent distributors and direct sales force. The Company’s segments are the medical market and the veterinary market. The Company’s medical market products include Piccolo chemistry analyzers and consumable products. The Company develops, manufactures and sells the Piccolo Xpress chemistry analyzer for use in human patient care to provide clinicians with blood constituent measurements. The Company’s veterinary market product offerings include VetScan chemistry analyzers and veterinary reagent discs, VetScan hematology instruments and related reagent kits, VetScan VSpro specialty analyzers and related consumables, VetScan i-STAT analyzers and related consumables and VetScan rapid tests. ABAXIS, INC. (NASDAQ:ABAX) Recent Trading Information
ABAXIS, INC. (NASDAQ:ABAX) closed its last trading session 00.00 at 55.02 with 183,221 shares trading hands.

Exit mobile version